The Human Bone Joint PrimaCell™: Normal Bone Joint Synovial Cells is for rapid (7-10 days) isolation and growth of normal human bone joint synovial cells from newborn or adult human bone joint tissues. This system features an optimal condition of tissue dissociation system, Bone Joint OptiTDS™ that yields 5-7 times of single cells more than most of the tissue dissociation protocols published in the literature. In addition, this system ensures a high viability of the target cells with improved gradient contained in the culture medium. With CHI's proprietary fibroblast inhibitory system, FibrOut™, cells are growing with minimal amount of the unwanted cells such as fibroblasts.

Human Bone Joint PrimaCell™ System (Cat No. 2-96011):
Human Bone Joint PrimaCell™ Normal Bone Joint Synovial Cells Protocols
Human Bone Joint Tissue Preparation Buffer : Normal Bone Joint Synovial Cells
Human Bone Joint OptiTDS™: Tissue Dissociation System
Human Bone Joint FibrOut™: Fibroblast Inhibitory System (for 500 ml medium)
Human Bone Joint PrimaCell™: Normal Bone Joint Synovial Cells Growth Medium
Human Bone Joint PrimaCell™: Normal Bone Joint Synovial Cells Growth Supplements with Serum (for 500 ml medium)

References:

[1] Park YE, Kim GT, Lee SG, Park SH, Baek SH, Kim SI, Kim JI, Jin HS. IL-32 aggravates synovial inflammation and bone destruction and increases synovial natural killer cells in experimental arthritis models. Rheumatol Int. 2012 Apr 19.
[2] Söderström K, Stein E, Colmenero P, Purath U, Müller-Ladner U, de Matos CT, Tarner IH, Robinson WH, Engleman EG. Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13028-33. Epub 2010 Jul 6.